ARS Pharmaceuticals (ARS Pharmaceuticals) Net Income : $-49.70 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. ARS Pharmaceuticals's Net Income for the three months ended in Mar. 2024 was $-10.29 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-49.70 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. ARS Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.11.

ARS Pharmaceuticals Net Income Historical Data

The historical data trend for ARS Pharmaceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARS Pharmaceuticals Net Income Chart

ARS Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Income

-1.07

-20.24

-34.68

-54.37

ARS Pharmaceuticals Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income	Get a 7-Day Free Trial							-14.96	-17.37	-14.87	-7.17	-10.29

ARS Pharmaceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

ARS Pharmaceuticals's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-54.365	+	0	+	0	+	0
=	-54.37

ARS Pharmaceuticals's Net Income for the quarter that ended in Mar. 2024 is calculated as

	Net Income		(Q: Mar. 2024 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-10.292	+	0	+	0	+	0
=	-10.29

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.70 Mil.

ARS Pharmaceuticals (NAS:SPRY) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

ARS Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

Earnings per Share (Diluted) (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-10.292	-	0)	/	96.486
	=	-0.11

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

ARS Pharmaceuticals Net Income Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

ARS Pharmaceuticals (ARS Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130

Website

https://www.ars-pharma.com

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Executives

Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laura Shawver	director, officer: Chief Executive Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033